PG
XLRN

PEAK6 Group’s Acceleron Pharma XLRN Stock Holding History

PEAK6 Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,603
Closed -$164K – 5494
2015
Q3 		$164K Buy
+6,603
New +$198K ﹤0.01% 3909
2015
Q2 		– Sell
-4,979
Closed -$190K – 5616
2015
Q1 		$190K Buy
+4,979
New +$198K ﹤0.01% 3486

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

PEAK6 Group's XLRN Position: Q4 2015 in Review

PEAK6 Group sold out of Acceleron Pharma (XLRN) in Q4 2015, closing a stake of 6,603 shares — an estimated $164K sold.

PEAK6 Group first reported a position in XLRN in Q1 2015 and held it in 2 quarters. The position peaked at $190K in Q1 2015. 125 funds tracked by Wall St. Rank hold XLRN as of Q4 2015.

  • PEAK6 Group reported no remaining Acceleron Pharma position as of Q4 2015 after selling out during the quarter.
  • PEAK6 Group sold 6,603 Acceleron Pharma shares in Q4 2015, an estimated $164K.
  • PEAK6 Group first reported a position in Acceleron Pharma in Q1 2015 and held it in 2 quarters.
  • PEAK6 Group's Acceleron Pharma position peaked at $190K in Q1 2015.
  • 125 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.